Search Results

Precision BioSciences, Inc. today announced its addition to the Russell Microcap® Index.

Precision BioSciences, Inc. today announced that members of management will participate in the following upcoming investor conferences in June.

Precision BioSciences, Inc. (Nasdaq: DTIL) today announced that it will publish financial results for the first quarter 2024 and provide a business update on Monday, May 13, 2024.

Precision BioSciences, Inc. (Nasdaq: DTIL) today announced that it had granted Caribou Biosciences, Inc., a leading CRISPR genome-editing cell therapy company, a non-exclusive, worldwide license, with the right to sublicense, to one of Precision’s foundational cell therapy patent families for use with CRISPR in the field of human therapeutics.